Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Myelodysplastic/Myeloproliferative Neoplasms Clinical Trial

Official title:

A Multi-center, Phase II, Single-arm Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05282719
• Other study ID #: MDS/MPN-01
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: April 2022
• Est. completion date: February 2023

Study information

• Verified date: March 2022
• Source: The First Affiliated Hospital of Soochow University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the efficacy of venetoclax combined with azacytidine in Myelodysplastic / myeloproliferative neoplasms（MDS/MPN）, so as to improve the overall survival and treatment status of MDS/MPN patients.

Description:

At present, there is no standardized treatment strategy for MDS/MPN. The purpose of our study is to explore the efficacy of venetoclax combined with azacytidine in the treatment of MDS/MPN, so as to improve the overall survival and treatment status of patients with MDS/MPN. After the participants were treated with four cycles of venetoclax combined with azacytidine, the efficacy was evaluated according to the 2015 adult MDS/MPN response criteria to determine the disease status. Participants with disease progression and intolerance withdrew from the study during treatment.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 33
• Est. completion date: February 2023
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, Age (years) >= 18;

2. Patients newly diagnosed or previously treated with MDS/MPNs (CMML, MDS/MPN-U, aCML) according to 2016 WHO diagnostic criteria: Initial diagnosis: CMML: CPSS-mol intermediate risk 2 and above; aCML; MDS/MPN-U. Previous treatment: HMA treatment failed.

3. Eastern Cooperative Oncology Group (ECOG) Performance status of 0,1, 2 ;

4. Liver function: Total bilirubin =3 upper limit of normal (ULN); aspartate aminotransferase (AST) =3 ULN; alanine aminotransferase (ALT)=3 ULN;

5. Renal function#Ccr =30 ml/min;

6. Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Acute myeloid leukemia

2. Myelodysplastic syndrome

3. Subjects who had previously been treated with Venetoclax

4. Subjects who are known to be allergic to ingredients of the study drug or their analogues

5. HIV infection

6. HBV-DNA or HCV-RNA positive

7. Subjects with grade 2 or above cardiac failure and those considered unsuitable for inclusion by the investigator

8. Subjects who are pregnant or breastfeeding

9. Subjects reject to participate in the study

Related Conditions & MeSH terms

• Adult
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasms
• Myeloproliferative Disorders
• Neoplasms

Intervention

Drug:
• venetoclax combined with azacitidine
On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology	Suzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Soochow University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR (equals the rates of complete remission [CR]+partial remission [PR]+complete cytogenetic remission [CCyR]+marrow response [MR[+clinical benefit [CB] )of venetoclax in combination with azacitidine.; CR and CCyR are shown in the secondary outcome measures below.; PR: Normalization of peripheral counts and hepatosplenomegaly with bone marrow blasts (and blast equivalents) reduced by 50%, but remaining>5% of cellularity except in cases of MDS/MPN with=5% bone marrow blasts at baseline.; MR: Optimal marrow response: Presence of all marrow criteria necessary for CR without normalization of peripheral blood indices.; Partial marrow response: Bone marrow blasts (and blast equivalents) reduced by 50%, but remaining>5% of cellularity, or reduction in grading of reticulin fibrosis from baseline on at least 2 bone marrow evaluations spaced at least 2 months apart.; CB: Hematology improvement, spleen response and symptom response.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Complete remission rate	Bone marrow: =5% myeloblasts (including monocytic blast equivalent in case of CMML) with normal maturation of all cell lines and return to normal cellularity Osteomyelofibrosis absent or equal to "mild reticulin fibrosis" (=grade 1 fibrosis).; Peripheral blood: Leukocyte=10×10E9 cells/L; Hemoglobin=11g/dL; Platelets=100×10E9/L, =450×10E9/L; Neutrophils=1.0×10E9/L; Blasts 0%; Neutrophil precursors reduced to=2%; Monocytes =1.0× 10E9/L.; Extramedullary disease: Complete resolution of extramedullary disease present before therapy (eg, cutaneous disease, disease-related serous effusions), including palpable hepatosplenomegaly.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Complete remission rate of bone marrow morphology	Presence of all marrow criteria necessary for CR without normalization of peripheral blood indices as presented above.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Hematology improvement (HI) rate	Percentages of participants with HI (erythroid/platelet/neutrophil responses); Erythroid response: Hemoglobin increase by=2.0 g/dL; Transfusion independence (TI) for =8 week for patients requiring at least 4 packed red blood cell transfusions in the previous 8 week; Only red blood cell transfusions given based on physician's judgment for a pretreatment Hgb of =8.5 g/dL will count in the red blood cell TI response evaluation.; Platelet response: TI when previously requiring platelet transfusions of at least a rate of 4 platelet transfusions in the previous 8 week; Pretreatment=20×10E9/L: increase from<20×10E9/L to>20×10E9/L and by at least 100%; Pretreatment>20×10E9/L but=100×10E9/L: absolute increase of =30×10E9/L.; Neutrophil response: Pretreatment=0.5×10E9/L at least 100% increase and an absolute increase=0.5×10E9/L; Pretreatment>0.5×10E9/L and=1.0×10E9/L, at least 50% increase and an absolute increase =0.5×10E9/L.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Complete cytogenetic remission rate	Resolution of previously present chromosomal abnormality (known to be associated with myelodysplastic, syndrome myeloproliferative neoplasms, or MDS/MPN), as seen on classic karyotyping with minimal of 20 metaphases or FISH.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Incidence of severe infection (=grade 3 )	Assessed using CTCAE 5	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Spleen response rate	Either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable.	Study start date to study end date, or death, whichever comes first, up to 4 years
Secondary	Symptom response rate	Improvement in symptoms as noted by decrease of =50% as per the MPN-SAF TSS scoring<20 were not considered eligible for measuring clinical benefit.	Study start date to study end date, or death, whichever comes first, up to 4 years